Immutep Limited (IMMP) Key Metrics

NASDAQ: IMMPValuation, returns, debt and efficiency ratios over 10 years.

IMMP key metrics, FY2017–FY2026

Fiscal year ended June 30, 2026 · Australian dollars

IMMP returns How much profit the business earns on the capital it uses.

Return on equity−38.7 pts
−75.6%
FY2026 · hover or tap a bar for each year
FY2017: −30.3% (+145.3 pts)FY2018: −42.4% (−12.2 pts)FY2019: −56.2% (−13.7 pts)FY2020: −46.7% (+9.5 pts)FY2021: −56.1% (−9.4 pts)FY2022: −38.5% (+17.6 pts)FY2023: −34.6% (+3.9 pts)FY2024: −26.2% (+8.4 pts)FY2025: −36.9% (−10.7 pts)FY2026: −75.6% (−38.7 pts)
FY2017FY2026
Return on assets−30.3 pts
−64.6%
FY2026 · hover or tap a bar for each year
FY2017: −24.2% (+121.6 pts)FY2018: −31.1% (−6.9 pts)FY2019: −37.2% (−6.1 pts)FY2020: −30.9% (+6.3 pts)FY2021: −46.5% (−15.6 pts)FY2022: −35.0% (+11.5 pts)FY2023: −32.0% (+3.0 pts)FY2024: −24.5% (+7.5 pts)FY2025: −34.3% (−9.8 pts)FY2026: −64.6% (−30.3 pts)
FY2017FY2026
Free cash flow margin
−381.7%
FY2026 · hover or tap a bar for each year
FY2017: −201.7%FY2018: −296.1% (−94.4 pts)FY2020: −145.0%FY2021: −457.1% (−312.0 pts)FY2024: −930.6%FY2026: −381.7%
FY2017FY2026
Asset turnover+321.3%
0.12
FY2026 · hover or tap a bar for each year
FY2017: 0.11 (+2,547.7%)FY2018: 0.06 (−41.1%)FY2019: 0.00 (−95.0%)FY2020: 0.17 (+5,280.5%)FY2021: 0.06 (−65.0%)FY2022: 0.00 (−96.9%)FY2023: 0.03 (+1,418.4%)FY2024: 0.02 (−21.6%)FY2025: 0.03 (+27.8%)FY2026: 0.12 (+321.3%)
FY2017FY2026

IMMP returns on capital

ROEROICROA

Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.

IMMP debt vs cash

Total debtCash & short-term investments

Debt includes short- and long-term borrowings and, where reported, lease liabilities.

IMMP key metrics in Australian dollars

FY2017–FY2026
Immutep Limited key metrics by fiscal year
FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Returns & profitability
Return on equity (ROE)−75.6%−36.9%−26.2%−34.6%−38.5%−56.1%−46.7%−56.2%−42.4%−30.3%
Return on invested capital (ROIC)—−805.2%−591.9%−407.9%−168.8%−156.5%−80.4%−100.3%−50.3%−37.4%
Return on assets (ROA)−64.6%−34.3%−24.5%−32.0%−35.0%−46.5%−30.9%−37.2%−31.1%−24.2%
Return on tangible assets−94.9%−41.0%−22.1%−28.9%−35.2%−43.2%−42.9%−69.0%−44.5%−58.8%
Free cash flow margin−381.7%—−930.6%——−457.1%−145.0%—−296.1%−201.7%
Financial health
Total debtA$1.0MA$1.6MA$1.6MA$1.2MA$1.7MA$2.8MA$9.1MA$7.6MA$6.6MA$5.8M
Cash & short-term investmentsA$68.9MA$129.7MA$181.9MA$123.4MA$80.0MA$60.1MA$26.3MA$16.6MA$23.5MA$12.2M
Net debt−A$67.8M−A$128.1M−A$180.3M−A$122.2M−A$78.3M−A$57.3M−A$17.3M−A$8.9M−A$16.8M−A$6.5M
Debt / equity0.020.010.010.010.020.040.270.310.200.22
Debt / assets0.010.010.010.010.020.030.190.190.140.17
Current ratio5.6911.6918.2513.8114.1612.819.264.447.436.05
Quick ratio5.6911.6918.0713.8114.3313.879.264.447.435.80
Interest coverage————-367.2—————
Working capitalA$66.5MA$136.3MA$180.9MA$125.2MA$84.4MA$63.1MA$27.8MA$18.2MA$24.8MA$13.3M
Invested capital−A$6.3MA$15.6MA$9.2MA$14.3MA$15.8MA$16.0MA$16.0MA$15.5MA$16.7MA$20.1M
Tangible asset valueA$60.0MA$136.4MA$181.3MA$127.0MA$83.5MA$60.4MA$18.1MA$7.4MA$15.2MA$7.5M
Net current asset valueA$58.9MA$135.7MA$179.3MA$124.0MA$82.7MA$59.7MA$17.9MA$7.4MA$15.2MA$7.5M
Capital allocation
Dividends paid———A$0A$0—A$0A$0A$0A$0
Share buybacks (net)———————A$0A$0A$0
Capex / revenue0.6%0.9%24.3%1.3%13.4%0.4%0.3%29.6%0.5%0.2%
Capex / depreciation0.040.020.430.020.010.010.010.020.010.00
Stock-based compensation / revenue—23.1%46.8%57.1%872.7%44.1%23.0%1,131.8%86.1%20.4%
R&D / revenue526.6%1,217.6%1,081.4%821.3%18,396.3%446.2%272.4%11,869.3%379.8%178.3%
SG&A / revenue67.3%171.4%230.4%401.7%4,232.1%162.6%84.6%4,384.9%275.3%103.0%
Efficiency
Days sales outstanding123.4273.8737.8851.015,530.2449.6210.211,376.1393.8102.1
Days of inventory on hand——8.4-98.1-598.6-59.90.00.011.7132.3
Days payables outstanding861.627.740.6735.9414.936.734.145.950.3182.3
Cash conversion cycle (days)-738.2246.1705.616.914,516.7353.0176.111,330.2355.252.1
Receivables turnover2.961.330.490.430.020.811.740.030.933.57
Payables turnover0.4213.178.990.500.889.9510.717.957.252.00
Inventory turnover——43.63———22,472,648.0016,591,201.0031.122.76
Asset turnover0.120.030.020.030.000.060.170.000.060.11
Average receivablesA$4.8MA$3.8MA$7.8MA$8.2MA$7.2MA$4.8MA$4.3MA$4.4MA$2.8MA$1.2M
Average payablesA$5.7MA$4.7MA$4.6MA$4.2MA$2.3MA$1.7MA$2.1MA$2.1MA$1.4MA$850,008
Average inventory——A$952,234−A$554,160−A$3.4M−A$2.8MA$1A$1A$321,000A$616,962
Intangibles / total assets1.8%4.6%4.1%6.4%10.3%15.7%32.6%41.8%39.0%54.4%

Computed from IMMP's annual financial statements (latest annual report filed June 30, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in Australian dollars; data from EODHD. Averages use the opening and closing balance of each year.

IMMP valuation and financial ratios

Immutep earned a return on equity of −75.6% in fiscal 2026. It ended the year with A$1.0 million of debt and A$68.9 million in cash and short-term investments, a net cash position of A$67.8 million.

See the IMMP income statement, the IMMP chart for price history, or the IMMP stock overview for the latest quote and news.

IMMP key metrics FAQ

What is Immutep's return on equity?

Immutep's return on equity (ROE) was −75.6% in fiscal 2026: net income of -A$77.6 million on average shareholders' equity of A$102.6 million.

How much debt does Immutep have?

Immutep had total debt of A$1.0 million at the end of fiscal 2026, a debt-to-equity ratio of 0.02 and more cash than debt.

What is Immutep's current ratio?

Immutep's current ratio was 5.69 at the end of fiscal 2026: current assets were 5.69 times current liabilities.

Biotechnology key metrics